ESMO 2019 | Lurbinectedin monotherapy is active in progressive malignant pleural mesothelioma: SAK 17/16 results

Yannis Metaxas, MD, Cantonal Hospital Grison, Chur, Switzerland, discusses the results of the SAKK 17/16 trial of lurbinectedin as a second or third line palliative chemotherapy in malignant pleural mesothelioma (NCT03213301). He highlights the next steps of comparing this treatment to the current standard of care. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.